Oric Pharmaceuticals (ORIC) Expected to Announce Quarterly Earnings on Tuesday

Oric Pharmaceuticals (NASDAQ:ORIC) will likely be announcing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 4:00 PM ET.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Tuesday, August 12th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). On average, analysts expect Oric Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oric Pharmaceuticals Stock Down 0.9%

Oric Pharmaceuticals stock traded down $0.11 during mid-day trading on Tuesday, reaching $12.58. 262,067 shares of the company’s stock were exchanged, compared to its average volume of 1,157,480. The business’s fifty day simple moving average is $11.82 and its 200 day simple moving average is $9.72. The firm has a market capitalization of $1.22 billion, a PE ratio of -6.69 and a beta of 1.66. Oric Pharmaceuticals has a one year low of $3.90 and a one year high of $14.93.

Insider Buying and Selling at Oric Pharmaceuticals

In other news, CEO Jacob Chacko sold 125,000 shares of the business’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $10.80, for a total value of $1,350,000.00. Following the transaction, the chief executive officer directly owned 656,419 shares in the company, valued at $7,089,325.20. The trade was a 16.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Dominic Piscitelli sold 11,000 shares of the business’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $14.52, for a total value of $159,720.00. Following the completion of the transaction, the chief financial officer owned 48,317 shares in the company, valued at $701,562.84. The trade was a 18.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 261,000 shares of company stock worth $3,024,703 over the last quarter. 5.55% of the stock is owned by company insiders.

Institutional Investors Weigh In On Oric Pharmaceuticals

Large investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Oric Pharmaceuticals by 1,331.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company’s stock worth $2,841,000 after purchasing an additional 473,600 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Oric Pharmaceuticals by 1,102.4% during the second quarter. BNP Paribas Financial Markets now owns 86,755 shares of the company’s stock worth $881,000 after acquiring an additional 79,540 shares during the last quarter. Brevan Howard Capital Management LP bought a new stake in Oric Pharmaceuticals during the second quarter worth approximately $352,000. Ameriprise Financial Inc. increased its stake in Oric Pharmaceuticals by 7.5% during the second quarter. Ameriprise Financial Inc. now owns 38,864 shares of the company’s stock worth $394,000 after acquiring an additional 2,706 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in Oric Pharmaceuticals by 49.7% during the second quarter. Jane Street Group LLC now owns 46,711 shares of the company’s stock worth $474,000 after acquiring an additional 15,513 shares during the last quarter. 95.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ORIC has been the topic of several recent research reports. JPMorgan Chase & Co. reduced their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, August 14th. Zacks Research upgraded Oric Pharmaceuticals to a “hold” rating in a report on Tuesday, August 12th. LADENBURG THALM/SH SH started coverage on Oric Pharmaceuticals in a report on Tuesday, July 8th. They issued a “buy” rating and a $15.00 price objective for the company. HC Wainwright decreased their target price on Oric Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Thursday, August 14th. Finally, Guggenheim started coverage on Oric Pharmaceuticals in a research report on Thursday, September 4th. They issued a “buy” rating and a $18.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.83.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.